Table 4 GV37 TCR contacts with HLA-C*12:02 and the KF9 peptide

From: Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope

TCR segment

TCR residues

HLA-C*12:02 residue

Bond type

CDR1α

Thr25

Arg62

VdW

CDR1α

Asp26

Arg62

VdW

CDR1α

Ser28-Oγ

Thr163-Oγ1

VdW, HB

CDR1α

Thr30

Gln155, Ala158

VdW

CDR1α

Tyr31-OH

Glu154-Oε1, Gln155

VdW, HB

CDR2α

Phe50

Glu154, Ala158

VdW

CDR3α

Glu93

Gln155

VdW

CDR3α

Gly94-N-O

Gln155-Oε1

VdW, HB

CDR3α

Thr96

Arg69

VdW

CDR3α

Pro97

Arg69

VdW

FWβ

Tyr48

Arg69

VdW

CDR2β

Glu52-Oε1

Arg79-Nη1

VdW, SB

CDR2β

Ala53

Val76, Arg79

VdW

CDR2β

Gln54

Gln72

VdW

FWβ

Leu55

Arg69, Gln72, Ala73

VdW

FWβ

Asp56-Oδ2

Arg69-Nε-Nη2, Gln65-Nε2

VdW, HB, SB

FWβ

Ser58-Oγ

Gln65-Nε2

HB

CDR3β

Leu96

Ala149

VdW

CDR3β

Ala97

Ala150

VdW

CDR3β

Ala100

Ala150, Gln155

VdW

CDR3β

Gly101-O

Arg151-Nε

VdW, HB

CDR3β

Gly102

Arg151

VdW

CDR3β

Val103

Ala149

VdW

TCR segment

TCR residues

KF9 residue

Bond type

CDR1α

Asp26-Oδ1

Lys1-Nζ

VdW, SB

CDR1α

Ser28-Oγ

Lys1-Nζ

VdW, HB

CDR3α

Glu93-O-Oε1

Asn4-Nδ2

VdW, HB

CDR3α

Gly94

Val5

VdW

CDR3α

Asn95-N-Nδ2

Val5-O, Thr6-O, Gln7

VdW, HB

CDR3α

Thr96

Asn4

VdW

CDR2β

Gln50-Ne2-Oε1

Gln7-Oε1, Ala8

VdW, HB

CDR3β

Ala97

Gln7

VdW*

  1. CDR Complementarity Determining Region, FW framework, VdW Van der Walls interaction, cut off 4 Å, HB Hydrogen bond, cut off 3.5 Å, SB salt bridge interaction cut off 5 Å. * VdW interaction at 4.01 Å (calculated by Contact software in CCP4).